Alex Pasteur is a partner in F-Prime Capital based in London, UK. He has worked in life sciences since 2001. He covers investments in therapeutics, medical devices and healthcare IT that are based in Europe, a portfolio that currently includes Orchard Therapeutics, Acacia Pharma Limited, Pulmocide Limited and Adaptimmune Therapeutics PLC (NASDAQ: ADAP).
He previously worked at MVM Life Science Partners LLP in the USA and Europe and was responsible for investments in Cara Therapeutics Inc., Vantia Ltd and Xention Pharma Ltd. Alex earned a M.A. in Natural Sciences and a Ph.D. in Chemistry from Cambridge University.